Sotrovimab, an anti-severe acute respiratory syndrome-coronavirus 2 monoclonal antibody is being utilized to prevent progression of coronavirus disease 2019 (COVID-19). Therefore, to understand its benefits, we have conducted a retrospective analysis of all non-hospitalized patients with symptomatic COVID-19 who received a single infusion of sotrovimab and/or oral favipiravir at any Dubai COVID-19 related healthcare center between July 1, 2021, and October 31, 2021. The main outcome was to evaluate the risk of hospitalization for patients with COVID-19 or all-cause death within 28 days of treatment initiation. In this analysis, which included 10,882 patients (1,135 in the sotrovimab group, 2,653 in the sotrovimab/favipiravir group, and 7,094 in the favipiravir group), sotrovimab or sotrovimab/favipiravir reduced the risk of hospitalization (13 patients (1.5%) in the sotrovimab group and 71 patients (2.9%) in the sotrovimab/favipiravir group vs. 251 patients (4%) in the favipiravir group; hazard ratio (HR) for sotrovimab: 0.16, 95% confidence interval (CI): 0.09–0.28, P < 0.001; and for sotrovimab/favipiravir, HR: 0.42, 95% CI: 0.32–0.56, P < 0.001), or death by day 28 from the start of treatment (no death in the sotrovimab group and 2 deaths in the the sotrovimab/favipiravir group vs. 10 deaths in the favipiravir group; odds ratio: 0.18, 95% CI: 0.04 to 0.81, P = 026). Safety was assessed in all the 3,788 patients in the sotrovimab and sotrovimab/favipiravir groups, and the reported adverse events were by 34 patients (<1%). In conclusion, sotrovimab was found to reduce the risk of progression of COVID-19 when administrated early to non-hospitalized patients with symptomatic COVID-19. No safety concern was detected.

中文翻译：

---

Sotrovimab 降低了阿拉伯联合酋长国大量人群队列中与 COVID-19 相关的住院或死亡风险

Sotrovimab 是一种抗严重急性呼吸系统综合症冠状病毒 2 型单克隆抗体，用于预防 2019 年冠状病毒病（COVID-19）的进展。因此，为了解其益处，我们对 2021 年 7 月 1 日期间在迪拜任何 COVID-19 相关医疗中心接受单次输注 sotrovimab 和/或口服 favipiravir 的所有有症状 COVID-19 患者进行了回顾性分析和 2021 年 10 月 31 日。主要结果是评估 COVID-19 患者住院或治疗开始后 28 天内全因死亡的风险。在这项分析中，包括 10,882 名患者（sotrovimab 组 1,135 名，sotrovimab/favipiravir 组 2,653 名，favipiravir 组 7,094 名），P  < 0.001；对于 sotrovimab/favipiravir，HR：0.42，95% CI：0.32–0.56，P  < 0.001），或治疗开始后第 28 天死亡（sotrovimab 组无死亡，sotrovimab/favipiravir 组有 2 例死亡对比法匹拉韦组 10 例死亡；比值比：0.18，95% CI：0.04 至 0.81，P  = 026）。在 sotrovimab 和 sotrovimab/favipiravir 组的所有 3,788 名患者中评估了安全性，报告的不良事件为 34 名患者 (<1%)。总之，发现 sotrovimab 在早期对有症状 COVID-19 的非住院患者给药时，可以降低 COVID-19 进展的风险。没有检测到安全问题。